Chris Williams - Autolus Therapeutics Senior Development
| AUTL Stock | USD 2.98 0.04 1.36% |
Executive
Chris Williams is Senior Development of Autolus Therapeutics
| Age | 44 |
| Address | The Mediaworks, London, United Kingdom, W12 7FP |
| Phone | 44 20 3829 6230 |
| Web | https://www.autolus.com |
Autolus Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2161) % which means that it has lost $0.2161 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.822) %, meaning that it created substantial loss on money invested by shareholders. Autolus Therapeutics' management efficiency ratios could be used to measure how well Autolus Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.58. The value of Return On Capital Employed is expected to slide to -0.62. At this time, Autolus Therapeutics' Other Current Assets are quite stable compared to the past year. Non Currrent Assets Other is expected to rise to about 2.6 M this year, although the value of Total Assets will most likely fall to about 275.2 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Scott Harris | Terns Pharmaceuticals | N/A | |
| Debra Sieminski | Terns Pharmaceuticals | N/A | |
| David MS | Ikena Oncology | N/A | |
| Rose Weldon | Cullinan Oncology LLC | N/A | |
| John Stubenrauch | Day One Biopharmaceuticals | N/A | |
| Ray Knox | Lyra Therapeutics | N/A | |
| Alexander Constan | Ikena Oncology | N/A | |
| MBA III | Celcuity LLC | 63 | |
| Gina JD | Amylyx Pharmaceuticals | 53 | |
| Emil MD | Terns Pharmaceuticals | 44 | |
| Robert Richard | Lyra Therapeutics | 66 | |
| Pamela Danagher | Terns Pharmaceuticals | N/A | |
| Tammy Sarnelli | Amylyx Pharmaceuticals | N/A | |
| Nathan Ihle | Bolt Biotherapeutics | N/A | |
| Allison Nance | Lyra Therapeutics | N/A | |
| Robert MD | Lyra Therapeutics | N/A | |
| Rebecca Cohen | Ikena Oncology | N/A | |
| MBA MD | Celcuity LLC | N/A | |
| Daron Evans | Rezolute | 50 | |
| Robert Arbeit | X4 Pharmaceuticals | 76 | |
| JD Esq | Acumen Pharmaceuticals | 53 | |
Management Performance
| Return On Equity | -0.82 | ||||
| Return On Asset | -0.22 |
Autolus Therapeutics Leadership Team
Elected by the shareholders, the Autolus Therapeutics' board of directors comprises two types of representatives: Autolus Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Autolus. The board's role is to monitor Autolus Therapeutics' management team and ensure that shareholders' interests are well served. Autolus Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Autolus Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Olivia Manser, Director Relations | ||
| David Brochu, Senior Officer | ||
| Chris Williams, Senior Development | ||
| Robert Dolski, Chief Officer | ||
| Lucinda Crabtree, Chief Officer | ||
| Robert MD, Executive Director | ||
| Alexander Swan, Senior Officer | ||
| Christian Itin, CEO Director | ||
| MBBS MD, Senior Founder | ||
| Brent Rice, Chief VP | ||
| Christopher Vann, Senior COO | ||
| Alex Driggs, Senior Secretary | ||
| ACA BEcon, Advisor |
Autolus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Autolus Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.82 | ||||
| Return On Asset | -0.22 | ||||
| Operating Margin | (21.14) % | ||||
| Current Valuation | 177.56 M | ||||
| Shares Outstanding | 266.12 M | ||||
| Shares Owned By Insiders | 18.08 % | ||||
| Shares Owned By Institutions | 76.21 % | ||||
| Number Of Shares Shorted | 7.19 M | ||||
| Price To Earning | (19.33) X | ||||
| Price To Book | 1.64 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Autolus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Autolus Stock please use our How to buy in Autolus Stock guide.You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Autolus Therapeutics. If investors know Autolus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Autolus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.22) | Revenue Per Share 0.043 | Quarterly Revenue Growth 6.81 | Return On Assets (0.22) | Return On Equity (0.82) |
The market value of Autolus Therapeutics is measured differently than its book value, which is the value of Autolus that is recorded on the company's balance sheet. Investors also form their own opinion of Autolus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Autolus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Autolus Therapeutics' market value can be influenced by many factors that don't directly affect Autolus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Autolus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Autolus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Autolus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.